Could ABIOMED, Inc. (ABMD) Skyrocket Even More? The Stock Just Made Record High

June 14, 2018 - By Jeanette Kaplan

ABIOMED, Inc. (NASDAQ:ABMD) Logo

Investors sentiment decreased to 0.95 in Q1 2018. Its down 0.23, from 1.18 in 2017Q4. It turned negative, as 23 investors sold ABIOMED, Inc. shares while 135 reduced holdings. 67 funds opened positions while 83 raised stakes. 36.41 million shares or 0.08% less from 36.44 million shares in 2017Q4 were reported.
Moreover, Jennison Llc has 0.02% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 55,032 shares. Columbus Circle Investors stated it has 23,039 shares. Smithfield Trust Co reported 25 shares. Crow Point Prtnrs Limited Liability Co has invested 0.03% in ABIOMED, Inc. (NASDAQ:ABMD). Hamilton Lane Advisors Limited, Pennsylvania-based fund reported 3,685 shares. Security Tru holds 0.04% in ABIOMED, Inc. (NASDAQ:ABMD) or 400 shares. New Mexico Educational Retirement Board has invested 0.13% in ABIOMED, Inc. (NASDAQ:ABMD). Marathon Cap Mngmt holds 1,000 shares or 0.11% of its portfolio. Sheets Smith Wealth Management stated it has 5,898 shares. Driehaus Capital Management Ltd, Illinois-based fund reported 6,054 shares. State Of Tennessee Treasury Department accumulated 40,000 shares. Lord Abbett And Lc holds 0.04% or 49,401 shares in its portfolio. Ameriprise Fincl has 0.04% invested in ABIOMED, Inc. (NASDAQ:ABMD). Moreover, Earnest Prtn Ltd Liability has 0% invested in ABIOMED, Inc. (NASDAQ:ABMD). Citigroup invested in 0% or 2,306 shares.

Since February 20, 2018, it had 0 insider buys, and 5 sales for $31.65 million activity. $5.41M worth of ABIOMED, Inc. (NASDAQ:ABMD) shares were sold by Greenfield Andrew J. Shares for $7.93 million were sold by BOLT WILLIAM J on Monday, May 7. Shares for $4.70M were sold by PUHY DOROTHY E. Howley Michael G had sold 17,500 shares worth $6.09 million on Monday, May 7.

The stock of ABIOMED, Inc. (NASDAQ:ABMD) reached all time high today, Jun, 14 and still has $458.28 target or 4.00 % above today’s $440.65 share price. This indicates more upside for the $19.60B company. This technical setup was reported by Barchart.com. If the $458.28 PT is reached, the company will be worth $783.96M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 1.75% or $7.58 during the last trading session, reaching $440.65. About 494,747 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 190.17% since June 15, 2017 and is uptrending. It has outperformed by 177.60% the S&P500.

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on July, 26. They expect $0.80 EPS, up 77.78 % or $0.35 from last year’s $0.45 per share. ABMD’s profit will be $35.58M for 137.70 P/E if the $0.80 EPS becomes a reality. After $0.80 actual EPS reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 8 analysts covering Abiomed (NASDAQ:ABMD), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Abiomed had 12 analyst reports since December 21, 2017 according to SRatingsIntel. Piper Jaffray maintained it with “Buy” rating and $300.0 target in Thursday, February 1 report. Jefferies maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Thursday, December 21. Jefferies has “Buy” rating and $220.0 target. The firm has “Buy” rating given on Thursday, January 4 by Piper Jaffray. On Monday, April 9 the stock rating was maintained by Stephens with “Buy”. On Friday, February 16 the stock rating was maintained by SunTrust with “Buy”. The company was maintained on Thursday, February 1 by Jefferies. The rating was maintained by Morgan Stanley on Tuesday, May 1 with “Equal-Weight”. Stephens maintained the shares of ABMD in report on Friday, February 2 with “Buy” rating. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, February 2. The rating was maintained by Guggenheim with “Buy” on Friday, February 2.

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Investorplace.com which released: “Is This the Latest Booster for Medtronic PLC Stock?” on June 14, 2018, also Investorplace.com with their article: “7 A-Rated Stocks to Buy for the Second Half of 2018” published on June 08, 2018, Seekingalpha.com published: “Discovery Is Undervalued – Cramer’s Lightning Round (6/11/18)” on June 12, 2018. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: Seekingalpha.com and their article: “PRAH +3% on MidCap 400 move; ABMD to S&P 500” published on May 25, 2018 as well as Globenewswire.com‘s news article titled: “Abiomed to Present at the Jefferies 2018 Healthcare Conference” with publication date: May 29, 2018.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $19.60 billion. It also provides continuum of care to heart failure patients. It has a 179.86 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: